Core Insights - Axsome Therapeutics reported a total net product revenue of $171.0 million for Q3 2025, reflecting a 63% year-over-year growth and a 14% sequential growth from Q2 2025 [3] - The company has submitted a supplemental NDA for AXS-05 for the treatment of Alzheimer's disease agitation, addressing a significant unmet medical need [2][11] Financial Highlights - Total net product revenue for Q3 2025 was $171.0 million, up from $104.8 million in Q3 2024, marking a 63% increase year-over-year [3] - AUVELITY sales reached $136.1 million in Q3 2025, a 69% increase from $80.4 million in Q3 2024 [3] - SUNOSI generated $32.8 million in revenue for Q3 2025, representing a 35% year-over-year growth [3] - SYMBRAVO achieved $2.1 million in sales during its first full quarter of commercialization [3] - The net loss for Q3 2025 was $47.2 million, or $(0.94) per share, an improvement from a net loss of $64.6 million, or $(1.34) per share, in Q3 2024 [3] Commercial Highlights - AUVELITY prescriptions increased by 46% year-over-year, totaling approximately 209,000 in Q3 2025 [9] - Payer coverage for AUVELITY is approximately 85%, with 75% in commercial channels and 100% in government channels [9] - SUNOSI prescriptions rose by 12% year-over-year, with approximately 53,000 prescriptions written in Q3 2025 [9] - SYMBRAVO had approximately 5,000 prescriptions written in its first full quarter [9] Development Pipeline - AXS-05 is being developed for Alzheimer's disease agitation and has received FDA Breakthrough Therapy designation [11] - Axsome plans to initiate a Phase 3 trial of solriamfetol in ADHD in pediatric patients in Q4 2025 [12] - AXS-12 is set for NDA submission for the treatment of cataplexy in narcolepsy in Q4 2025 [13] - A Phase 3 trial of AXS-14 in fibromyalgia is also planned for Q4 2025 [17] Cash Position - Cash and cash equivalents totaled $325.3 million as of September 30, 2025, compared to $315.4 million at the end of 2024 [8]

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM), urging shareholders to contact the firm to discuss their rights [1][2]. Group 1: Shareholder Rights and Legal Options - Long-term shareholders of Axsome may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2][3]. - Shareholder involvement is emphasized as a means to improve company policies and enhance shareholder value through better management and accountability [3]. Group 2: Firm's Background and Services - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

Pipeline & Market Focus - Axsome Therapeutics has three drugs on the market and five in the pipeline [1] - The drugs have the potential to help approximately 150 million Americans suffering from brain disorders [1]

Core Insights - Axsome Therapeutics is transitioning from a development-stage company to a neuroscience-focused entity, with three drugs currently marketed and a robust late-stage pipeline [1] Company Overview - Axsome Therapeutics has successfully moved into the commercialization phase with three marketed drugs [1] - The company is developing a rich late-stage pipeline, indicating potential for future growth and revenue generation [1] Financial Analyst Background - Gamu Dave Innocent Pasi, a financial professional, has extensive experience in financial analysis and investment research, contributing to reputable publications [1] - He holds advanced qualifications in investments and portfolio management, emphasizing his expertise in the field [1] Investment Focus - The analyst is currently focused on building an international investment portfolio, aiming to share insights and strategies with the global investing community [1]

Core Insights - Axsome Therapeutics is transitioning from a development-stage company to a neuroscience-focused entity, with three drugs currently marketed and a robust late-stage pipeline [1] Company Overview - Axsome Therapeutics has successfully moved into the commercialization phase with three marketed drugs [1] - The company is developing a rich late-stage pipeline, indicating potential for future growth and revenue generation [1] Financial Analyst Background - Gamu Dave Innocent Pasi, a financial professional, has extensive experience in financial analysis and investment research, contributing to reputable publications [1] - He holds advanced qualifications in investments and portfolio management, showcasing strong analytical skills [1] Investment Focus - The analyst is currently focused on building an international investment portfolio, emphasizing innovative solutions for financial inclusion and sustainability [1]

Group 1 - The Annual General Meeting (AGM) of Perenti for the year 2025 has commenced with a quorum present [2] - The meeting acknowledges the traditional owners of the land, specifically the Whadjuk people of the Nunga Nation, and pays respect to Aboriginal and Torres Strait Islander peoples [3] - Key members of the Perenti Board and Executive Committee are present at the meeting, including the Managing Director and CEO, Independent Non-Executive Directors, and various Presidents of divisions [4][5]

Core Insights - Axsome Therapeutics is actively participating in Mental Illness Awareness Week (MIAW) to promote mental health awareness and community support [1][2] - The theme for this year's MIAW is "Building Community: Supporting Mental Well-being Together," emphasizing the importance of grassroots advocacy and local action [1][2] - Axsome is committed to supporting individuals with mental health conditions and collaborates with organizations like NAMI to provide resources and reduce stigma [3][4] Company Overview - Axsome Therapeutics is a biopharmaceutical company focused on treating central nervous system (CNS) disorders, with a portfolio that includes FDA-approved treatments for major depressive disorder, narcolepsy, obstructive sleep apnea, and migraines [4] - The company aims to address critical gaps in care and develop innovative products that improve patient outcomes, impacting over 150 million people in the U.S. [4] - Axsome partners with national and global advocacy organizations to strengthen communities and provide support for those affected by mental health challenges [3][4] Mental Health Statistics - Over 1 in 5 adults in the U.S. experience mental illness each year, and more than 1 in 7 youth aged 6-17 also face mental health conditions annually [3] - Nearly 90% of individuals living with depression report difficulties in work, home, or social activities due to their symptoms, highlighting the significant impact of depression [3]

Core Viewpoint - Axsome Therapeutics, Inc. is set to report its financial results for Q3 2025 on November 3, 2025, before U.S. market opening, followed by a conference call for discussion [1] Company Overview - Axsome Therapeutics is a biopharmaceutical company focused on treating central nervous system (CNS) disorders, with a portfolio that includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness related to narcolepsy and obstructive sleep apnea, and migraine [3] - The company aims to address significant gaps in care by developing differentiated products with novel mechanisms of action, impacting over 150 million people in the U.S. [3] Financial Communication - A live conference call will be held at 8:00 a.m. Eastern Time on November 3, 2025, to discuss the financial results and provide a business update [1][2] - Participants can join the call via a toll-free domestic number or an international number, with a live webcast available on the company's website [2]

Axsome Therapeutics has three drugs on the market and five in the pipeline, with the potential to help some 150 million Americans suffering from brain disorders. https://t.co/LKtMi6FYxP ...

分组1 - Jane Goodall, a renowned zoologist and animal rights activist, passed away at the age of 91, known for her groundbreaking discoveries about chimpanzees and her influence on women in science [1] - Elon Musk has reached a new milestone, becoming the first person to be worth $500 billion, with projections suggesting he could become the world's first trillionaire by 2033 [3] - The U.S. government shutdown has led to a rally in bitcoin and gold prices as investors seek safe havens, although such shutdowns are typically short-lived with limited economic impact [4] 分组2 - U.S. private sector employment fell more than expected in August, indicating a deceleration in the job market, with potential implications for the Federal Reserve's upcoming policy meeting [5] - Saronic, an autonomous speedboat startup, raised $600 million at a $4 billion valuation, aiming to revive the U.S. shipbuilding industry by mass-producing small, cheap, autonomous vessels [6] - Axsome Therapeutics, focused on brain disorders, reported a revenue of $495 million for the 12 months ending in June, a 70% increase from the previous year, although it remains unprofitable with a net loss of $247 million [12][13]